CDX is a Mass-Market Consumer and SaaS Company

CardieX is a Global Health Technology Company that Develops Solutions for Large Scale Population Health Disorders

Under the ATCOR.X brand, the CardieX develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).

I believe most of the investing community are yet to wake up to the new CardieX business model.

It is still viewed as primarily an FDA-cleared and patented medical device company that focuses on hypertension, cardiovascular disease and other vascular health disorders; in use worldwide at major medical institutions and research institutions. Fabulous product, but limited $ market potential, and built into current SP.

What the market doesn't understand is that the business is fundamentally changing.

By developing patent technology that allows it to transfer it's knowledge for measuring arterial stiffness and central blood pressure waveforms onto wearable devices, it now has the ability to sell a product to every human being in the world via weaarbles. This will happen in 2021, via licensing to current wearable manufacturers and launching their own product.

Nice.

But where this company has really re-invented itself is through the SaaS business model. Anyone who purchases a wearable to monitor their cardiovascular health will want to download the ArtyNet App, and pay the monthly subscription to connect to the digital platform. Why bother with the wearable otherwise! The company nominated fee is $10 per month to subscribe.

With over 50% of the adult population in the USA with hypertension, let alone the rest of the world, it is easy to project 20M - 50M users enrolled within 3 years of launch. At $120 per year per user .... do the maths.

IMO, In 3 Years , CardieX will be primarily known as a mass-market and SaaS business, that also has a small division selling specialist equipment to medical and research institutions.